Modality
ASO
MOA
TYK2i
Target
FGFR
Pathway
Sphingolipid
PSPBCCMigraine
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
~May 2020
→ ~Aug 2021
Phase 2
Nov 2021
→ Dec 2028
Phase 2Current
NCT08433116
2,779 pts·PSP
2021-11→2028-04·Recruiting
NCT04900805
291 pts·BCC
2024-02→2028-12·Recruiting
3,070 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-04-152.0y awayPh2 Data· PSP
2028-12-082.7y awayPh2 Data· BCC
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Recruit…
P2
Recruit…
Catalysts
Ph2 Data
2028-04-15 · 2.0y away
PSP
Ph2 Data
2028-12-08 · 2.7y away
BCC
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08433116 | Phase 2 | PSP | Recruiting | 2779 | PASI75 |
| NCT04900805 | Phase 2 | BCC | Recruiting | 291 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| Cevitinib | Regeneron | Phase 3 | FGFR |